Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Hospira, Inc.
Biogen And Millennium May Be Ensnared In Tentacles Of Genentech’s Expired Cabilly Patent
Genentech claims Biogen and Millennium owe royalties on sales of Tysabri and Entyvio that were stockpiled when the Cabilly patent expired. Hospira faced similar litigation over its erythropoietin biosimilar and had to pay Amgen $70m in damages.
Finance Watch: VC Mega-Rounds Make A Comeback In March
Private Company Edition: After just seven venture capital rounds of $100m or more in January and February, five have been announced already in March, including a $200m series A round for Cargo Therapeutics, Chroma Medicine’s $135m series B financing and $112m for Noema’s series B.
China New Government Policies Taking Shape As Two Sessions Underway
Moderate growth goal and lingering impact from COVID policies dampen prospects of a quick recovery for China.
FY2022: Medtech Innovators Exchange Top 10 Placings
The leading global medtechs’ fiscal 2022 revenue reports are all in: Abbott Laboratories moved above Medtronic in MAT medtech revenues, while Philips Healthcare and Stryker finished the year with strong quarters and Roche dropped a few places.
- Other Names / Subsidiaries
- Javelin Pharmaceuticals, Inc.
- Mayne Pharma Limited
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.